OSLO, NORWAY--(Marketwire - August 30, 2010) - Bionor Pharma (
Henrik Lund has most recently headed up clinical development activities of Astra Zeneca in Europe, Asia and Latin America (43 countries). His previous commercial and management experience also includes positions with Rhone-Poulenc Rorer and Nycomed Imaging. Henrik Lund was one of the four new members who joined the Board of Directors of Bionor Pharma in May this year.
"We are very pleased that Henrik Lund has accepted our offer of the CEO position in Bionor Pharma," says Wenche Rolfsen, the chairwoman of Bionor Pharma. "His strong international background, clinical development experience, pharmaceutical insight and leadership style is perfectly suited to our needs. We are confident that he will be the right person to lead this company during the challenging next few years."
"Over the last couple of months I have gained an insight into the strong and innovative technology and exciting product portfolio of Bionor Pharma. This is a company with a promising future, and I am looking forward to contributing towards its success," says Henrik Lund.
Trond Syvertsen was co-founder and has been CEO of Bionor Pharma since 2004 and during this time has worked to obtain new distribution channels for products based on its soy technology platform. He also initiated and led the acquisition of Bionor Immuno AS in January 2010. Trond Syvertsen will continue to support the company during the next few months within Nutraceuticals business area.
"This change in management is a natural step for Bionor Pharma, which over the last few months has been transformed from a nutraceutical company to a biopharmaceutical company with its core business within vaccines for viral diseases. With this in mind it has been our objective to bring in leadership with experience in the key fields where we are active, and Henrik precisely fits this bill," comments Trond Syvertsen.
"Trond Syvertsen has done an excellent job, leading the acquisition of Bionor Immuno and building a new company, Bionor Pharma, which now is prepared for entering a new phase in its development," says Wenche Rolfsen. "The Board of Directors would like to thank Trond Syvertsen for his positive contributions during the transformation phase following the acquisition."
About Bionor Pharma
Bionor Pharma is an innovative biotech company developing pharmaceutical-grade peptide vaccines that stimulate cell-mediated or humoral immunity. Bionor Pharma carefully designs synthetic peptides from low-mutating parts of the virus that are modified to improve immunogenicity, resulting in enhanced efficacy and safety profiles. HIV is the first disease targeted, with the most advanced vaccine candidate, Vacc-4x, about to finish clinical phase IIb. Bionor Pharma's platform technology is broadly applicable, and the company has a humoral vaccine candidate for HIV, Vacc-C5 in pre-clinical phase, in addition to vaccine candidates for chronic infections such as Hepatitis C (HCV), Human Papilloma Virus (HPV) and Influenza. Bionor Pharma is listed on the Oslo Stock Exchange under the ticker ["BIONOR"].
Contact Information:
Contact information
Henrik Lund, MD
Deputy Chairman of the Board
+47 90 97 12 19